To assess whether intracerebroventricular leptin administration affects monodeiodinase type II (D2) activity in the tissues where it is expressed [cerebral cortex, hypothalamus, pituitary, and brown adipose tissue (BAT)], hepatic monodeiodinase type I (D1) activity was inhibited with propylthiouracil (PTU), and small doses of thyroxine (T4; 0.6 nmol⅐100 g body wt Ϫ1 ⅐day Ϫ1 ) were supplemented to compensate for the PTU-induced hypothyroidism. Two groups of rats were infused with leptin for 6 days, one of them being additionally treated with reverse triiodothyronine (rT3), an inhibitor of D2. Control rats were infused with vehicle and pair-fed the amount of food consumed by leptin-infused animals. Central leptin administration produced marked increases in D2 mRNA expression and activity in BAT, changes that were likely responsible for increased plasma T3 and decreased plasma T4 levels. Indeed, plasma T3 and T4 concentrations were unaltered by central leptin administration in the presence of rT3. The additional observation of a leptininduced increased mRNA expression of BAT uncoupling protein-1 suggested that the effect on BAT D2 may be mediated by the sympathetic nervous system. intracerebroventricular leptin; triiodothyronine; thyroid hormones THYROID HORMONES have long been known to play an important role in the regulation of energy balance, in particular by stimulating thermogenesis (37). Leptin, an adipocyte-derived hormone acting on hypothalamic neurons to decrease food intake, has also been shown to stimulate energy-dissipating mechanisms (16, 42, 43) . It can, therefore, be speculated that leptin may affect thermogenesis through an effect on thyroid hormones. In this respect, it is well documented that food restriction, a condition associated with low leptin levels, has profound effects on the hypothalamo-pituitarythyroid axis in rats, including low plasma thyroxine (T 4 ) and triiodothyronine (T 3 ) levels, as well as decreased TRH and TSH synthesis in the hypothalamus and the pituitary, respectively (27). Systemic administration of leptin in rats and mice has been shown to prevent the fasting-induced reduction in proTRH mRNA levels occurring in neurons of the paraventricular nucleus, as well as to restore to normal the decreased circulating T 4 and T 3 levels due to food restriction (1, 24). Intracerebroventricular administration of leptin in rats has also been shown to reverse the marked suppression of TSH secretion measured in food-restricted animals (36). Such a stimulatory effect of leptin on spontaneous TSH secretion during food restriction was shown to depend on the thyroid status, as it was not observed in hypothyroid rats (36).
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We have previously demonstrated (8) that central leptin administration in rats prevented the fall in plasma T 3 occurring during food restriction, whereas it was without effect on the decrease in serum TSH measured in these conditions. We also demonstrated (8) that hepatic deiodinase type I (D1) activity was decreased by food restriction, and that central leptin infusion completely prevented such a decrease. Under our experimental conditions of central leptin infusion, the peripheral plasma leptin levels were unchanged, indicating that the effects of leptin on hepatic D1 expression and activity had to be centrally elicited. Because central leptin administration has been shown to stimulate the sympathetic nervous system outflow (23), it could be hypothesized that leptin would influence hepatic D1 through an activation of this branch of the autonomic nervous system. However, D1 expression and activity are not known to be influenced by the sympathetic nervous system (or by catecholamines) (19) .
In view of these considerations, we postulated that central leptin administration might stimulate deiodinase type II (D2) activity, thus resulting in an increase in plasma T 3 levels, which would then be sufficient to increase D1 activity (19) . To test the hypothesis of a possible effect of leptin on D2, we used an in vivo approach allowing us to differentiate between the regulation of D1 and D2. This approach was based on the following considerations. The thyroid hormone metabolite reverse T 3 (rT 3 ) has been reported to strongly inhibit D2 activity (34) . However, the rapid metabolism of rT 3 by hepatic D1 in the adult rat (14, 17) hampers its in vivo use as a D2 inhibitor. By inhibiting D1 activity with propylthiouracil (PTU), we could expect to decrease rT 3 degradation and to therefore obtain high plasma levels of infused rT 3 that would inhibit D2 activity. The use of PTU would also reduce hepatic D1 activity to constantly low levels, excluding the possibility that leptin might affect plasma T 3 levels through an activation of this enzyme. Finally, the hypothyroid state induced by PTU would be partly compensated for by moderate T 4 supplementation to provide substrate for D2 activity while avoiding inhibition of D2 by T 4 (25, 41) .
On the basis of the aforementioned considerations and with the use of PTU-treated, T 4 -supplemented rats, the aims of the present study were 1) to determine whether the intracerebroventricular administration of leptin has an action on D2 in the tissues in which this enzyme is expressed, i.e., in the cerebral cortex, the hypothalamus, the pituitary gland, and brown adipose tissue (BAT); 2) to investigate what the consequences are on plasma T 3 levels of such a potential effect of central leptin administration on D2; and 3) to assess whether central leptin has a concomitant stimulatory effect on the sympathetic nervous system activity, as assessed by the measurement of the mRNA expression of BAT uncoupling protein-1 (UCP1).
MATERIALS AND METHODS
Animals. Eight-to nine-week-old male Wistar rats purchased from BRL (Basel, Switzerland) were housed under conditions of controlled temperature (23°C) and illumination (7:00 AM-7:00 PM). They were allowed ad libitum access to water and standard laboratory chow (Provimi Lacta, Cossonay, Switzerland).
Experimental procedure. All animals were made hypothyroid with PTU (FLUKA Chemie, Buchs, Switzerland) given in their drinking water at a dose of 0.025% during the whole experimental period. After 2 wk, the mean body weight of the animals was 165 Ϯ 2 g, with a daily rate of weight gain of 2.3 Ϯ 1.1 g, indicating that the PTU treatment did not result in weight loss, although the rate of body weight gain was lower than in the absence of PTU (data not shown). At that time, they were anesthetized with intramuscular ketaminexylazine used at 45 and 9 mg/kg, respectively (Parke-Davis and Bayer, Leverkusen, Switzerland), and equipped with a cannula positioned in the right lateral cerebral ventricle. After 1 wk of recovery, subcutaneously implanted osmotic minipumps delivering vehicle or leptin were connected to the intracerebroventricular infusion cannula via a polyethylene catheter, as previously described (33) . Minipumps (model 2001; Alza, Palto Alto, CA) infused 10 g of leptin (Ala-100, human leptin analog provided by Eli Lilly, Indianapolis, IN) per day for 6 days or its vehicle, isotonic saline. At the beginning of the respective central infusions, all PTU-treated hypothyroid rats were supplemented by daily intraperitoneal injections of T 4 for 3 days (0.6 nmol ⅐ 100 g body wt Ϫ1 ⅐ day Ϫ1 ). Subsequently and for the remaining 3 days of the experiments, the intraperitoneal T 4 injections were replaced by a continuous T4 infusion, at the same dose of 0.6 nmol ⅐ 100 g body wt Ϫ1 ⅐ day Ϫ1 , by means of the subcutaneous minipumps. In one-half of the leptin-infused rats, a subcutaneous infusion of rT 3 was carried out for 3 days at a rate of 25 nmol ⅐ rat Ϫ1 ⅐ day Ϫ1 via the same minipumps as those used for T4 supplementation. Three groups of rats were thus investigated, all animals receiving PTU and T4 substitution: i.e., controls, leptin-infused, and leptin plus rT3-infused animals (5-7 rats per group). The saline-infused control group was pair-fed the amount of food consumed by leptin-infused animals to determine the impact of decreased food intake per se. The pair-feeding regimen was performed as follows. Average daily food intake of the leptin-infused group was calculated; one-third of this amount of food was given at 8:00 AM, and the remaining two-thirds were given before the lights were turned off (6:00 PM), on the basis of a preliminary study of food consumption during the day and the night.
T 4 and, when used, rT3 were dissolved in 0.1 N NaOH and further diluted to the final concentration with 0.02 N NaOH in 0.9% NaCl and 0.5% hypothyroid rat serum [pool of serum sampled from 3-wk methimazole (2-mercapto-1-methylimidazole; FLUKA Chemie)-treated rats at a dose of 0.2 g/l in the drinking water]. Adequate dosages of T 4 and rT3 were chosen during preliminary experiments.
At the end of the experiments, the animals were killed by decapitation. Liver, BAT, cerebral cortex, hypothalamus, and pituitary were removed, immediately frozen, and stored at Ϫ70°C.
All procedures used were approved by the Office Vétéri-naire Fédéral et Cantonal, Geneva, Switzerland.
Quantitative RT-PCR procedure. Total RNA was extracted from frozen tissue samples with TRIzol reagent (Life Technologies GIBCO-BRL, Rockville, MD). RNA integrity was assessed by performing a 1% agarose gel electrophoresis in 1ϫ Tris-borate-EDTA, and its concentration was determined by spectrophotometry. cDNA templates for RT-PCR were obtained using 2.5 g of total RNA. Reverse transcription reaction was performed with random hexamers (Microsynth, Geneva, Switzerland), dNTPs, the RNAse inhibitor RNAsin (Catalys, Promega, Madison, WI), and the MMLV-RT Enzyme Kit (Life Technologies GIBCO-BRL).
The real-time PCR (Lightcycler; Roche Diagnostics, Basel, Switzerland) reaction is an automated quantitative PCR obtained by continuous monitoring of the fluorescence emitted upon binding of the SYBR Green I dye to the doublestranded DNA. Amplification of cyclophilin A, D1, D2, and UCP1 cDNAs was performed with the SYBR Green I DNA master kit (Roche Diagnostics, Mannheim, Germany) according to the light cycler standard protocol, using ϳ70 ng of template cDNA. Primers for cyclophilin and D1 were used at a final concentration of 0.5 M, and primers for D2 and UCP1 were used at 0.125 M. The annealing temperature was 57°C for the D1 and D2 and 55°C for the UCP1 primer sets. After each run, a relative quantification of amplified PCR product in the different samples was performed. This was based on the relative comparison of the PCR products during the log-linear phase of the amplification process. A standard curve was used to obtain the relative concentration of the target gene, and the results were corrected according to the concentration of cyclophilin, used as the housekeeping gene.
Primer sequences. Primers for rat cyclophilin A, D1, D2, and UCP1 were designed on-line with Primer 3 software (http:// www.genome.wi.mit.edu/cgi-bin/primer/primer3_www.cgi) and synthesized by Microsynth (Balgach, Switzerland). Primers were as follows: cyclophilin A: sense primer 5Ј-AGCACT-GGGGAGAAAGGATT-3Ј starting at 166, antisense primer 5Ј-CATGCCTTCTTTCACCTTCC-3Ј starting at 471, product size 306; D1: sense primer 5Ј-CCTCCACAGCTGACTTC-CTC-3Ј starting at 437, antisense primer 5Ј-TTCCAGAA-CAGCTCGGACTT-3Ј starting at 741, product size 305; D2: sense primer 5Ј-CAGTGAAGCGGAATGTCAGA-3Ј starting at 2842, antisense primer 5Ј-AGAGGCATGTTAGGT-GGGTG-3Ј starting at 3380, product size 539; UCP1: sense primer 5Ј-ACCCTGGCCAAGACAGAAG-3Ј starting at 369, antisense primer 5Ј-CAATCCTGAGGGAAGCAAAG-3Ј starting at 459, product size 91.
The adequacy of the different PCR products was verified by nucleic acid sequencing and agarose gel electrophoresis.
D1 and D2 activities. Tissues were homogenized in 10 volumes of 0.1 M phosphate (pH 7.2), 2 mM EDTA, and 1 mM DTT (P100E2D1 buffer). D2 activity was assayed in freshly prepared homogenates. Aliquots of homogenates were snapfrozen and stored at Ϫ80°C until analysis of D1 activities. D1 and D2 activities were assayed by monitoring the release of radioiodide from outer-ring-labeled rT 3 and T4, respectively. For hepatic D1 activity, liver homogenates (ϳ50 g protein/ ml) were incubated for 30 min at 37°C with 0.1 M rT 3 and 10 5 cpm of [3Ј,5Ј-125 I]rT3 in 0.1 ml of P100E2D10 buffer. Blank incubations were carried out in the absence of homogenate. Radioiodide production was analyzed as previously described (32) . Deiodinase activity of homogenates was corrected for nonenzymatic deiodination observed in the blanks. D2 activities in brain, pituitary, and BAT were determined by incubation of appropriately diluted homogenates for 60 min at 37°C with 1 nM (10 5 cpm) [3Ј,5Ј-125 I]T4 in the presence of 0.1 M T3 to block D3 and 0.1 mM PTU to block D1, if present. Blank incubations were carried out in the absence of homogenate. Release of 125 I was determined and corrected for nonenzymatic deiodination as described. In the assay of hepatic D1 activity, the samples were diluted 4,000 times, excluding a possible in vitro effect of the PTU used in vivo to inhibit D1 activity and making the animals hypothyroid. The same holds true for any putative effect of in vivo-infused rT 3 on the in vitro measurement of D2 activity. Note that D1 and D2 activities were analyzed using substrate concentrations of 0.1 M rT 3 and 1 nM T4, respectively, being approximately equal to their Km values. Very similar changes in hepatic D1 activities were observed in rats with different thyroid states by using 1 M instead of 0.1 M rT 3 as the substrate. Similarly, relative differences in BAT D2 activities between groups of rats subjected to various treatments were identical if D2 activity was measured at 10 nM instead of 1 nM T 4 as the substrate. These higher substrate concentrations provide near-maximum deiodination rates.
Type 3 deiodinase activity. Type 3 deiodinase (D3) activity was assayed by monitoring the production of radioactive 3,3Ј-diiodothyronine (3,3Ј-T 2) from outer-ring-labeled T3. Cerebral cortex homogenates (ϳ1 mg protein/ml) were incubated for 60 min at 37°C with 1 nM (2 ϫ 10 5 cpm) [3Ј-125 I]T3 in 0.1 ml of 100 mM phosphate (pH 7.2), 2 mM EDTA, and 50 mM DTT. Blank incubations were carried out in the absence of homogenate. The reactions were stopped by addition of 0.1 ml of ice-cold methanol on ice. The mixtures were centrifuged, and 0.1 ml of the supernatants was mixed with 0.1 ml of 0.02 M ammonium acetate (pH 4) and analyzed by HPLC. Samples of 0.1 ml were applied to a 250 ϫ 4.6 mm Symmetry C 18 column (Waters, Etten-Leur, The Netherlands) connected to an Alliance HPLC system (Waters) and eluted isocratically with a mixture of acetonitrile and 0.02 M ammonium acetate (33:67, vol/vol) at a flow of 1.2 ml/min. Radioactivity in the eluate was monitored on-line using a Radiomatic A-500 flow scintillation detector (Packard, Meriden, CT). Conversion of labeled T 3 to radioactive 3,3Ј-T2 was corrected for nonenzymatic deiodination as observed in the blanks.
Plasma hormones and metabolites. TSH and T4 levels were measured by RIAs (Immulite 2000; Diagnostic Product, Los Angeles, CA; rat TSH: L2KTS6; T4: L2KT4). Plasma T3 and rT3 levels were measured by in-house methods in Rotterdam (Erasmus University) with the following respective intraand interassay coefficients of variation: T3, 2-6 and 8%; rT3, 3-4 and 9-14%. More specifically, T3 was measured by RIA using a rabbit anti-T3 antiserum (final dilution 1:250,000) and [
125 I]T3 (20,000 cpm) (Amersham Pharmacia Biotech, Aylesbury, UK). Sample volume was 25 l, and incubation mixtures were prepared in 1 ml of RIA buffer [0.06 M barbital, 0.15 M HCl, 0.1% BSA, and 0.6 g/l 8-anilino-1-naphthalenesulfonic acid (Sigma)]. Mixtures were incubated in duplicate overnight at 4°C, and antibody-bound radioactivitry was precipitated using Sac-Cel cellulose-coupled second antibody (IDS, Boldon, UK). The lower limit of detection was 0.15 nmol/l. Plasma rT3 levels were determined using an inhouse-produced antiserum. The limit of detection was 0.04 nmol/l rT3.
Statistical analysis. The results were analyzed by one-way analysis of variance (ANOVA) followed by Tukey's procedure for multiple comparisons. The calculations were performed using the SigmaStat software (SPSS, Chicago, IL). A P value Ͻ0.05 was considered statistically significant.
RESULTS
Because the aim of the present study was to assess a potential role of leptin on the regulation of D2 with possible consequences on plasma thyroid hormone levels, the activity of hepatic D1 was inhibited by PTU, and the hypothyroid state induced by PTU was partly compensated for by moderate T 4 substitution. The pathways targeted by our experimental design are schematized in Fig. 1 . As shown in Table 1 , hepatic D1 activity of the animals studied was consistently low and was ϳ90% lower than that of euthyroid rats (see legend of Table 1 ). This was true for the three groups of rats investigated, i.e., control animals infused intracerebroventricularly (icv) with vehicle and pair-fed the amount of food consumed by the leptin-infused rats (i.e., ϳ40% reduction of food intake compared with ad libitum-fed controls), leptin-infused rats, and leptininfused rats receiving a 3-day subcutaneous rT 3 infusion. When rats were infused with rT 3 , their plasma levels of this thyroid hormone metabolite reached values that were much higher than those of controls (101.8 Ϯ 5.6 vs. 0.25 Ϯ 0.02 pmol/ml, P Ͻ 0.001). Figure 2 shows that, relative to pair-fed controls, the central leptin infusion resulted in a marked increase in BAT D2 activity (5-fold) and mRNA expression (2.5-fold). The activity of this BAT enzyme was decreased by rT 3 administration to reach levels that were similar to those observed in the vehicle-infused, pair-fed control group. In contrast, the D2 mRNA expression remained elevated in leptin-treated animals receiving rT 3 . In tissues other than BAT (e.g., cortex, hypothalamus, pituitary), and as depicted in Table 2 , central leptin administration had no effect on D2 activity. rT 3 alongside leptin brought about a reduction in the activity of this enzyme in the pituitary only.
The effect of leptin on plasma levels of thyroid hormones is depicted in Fig. 3 . Compared with pair-fed controls, central leptin administration resulted in a 50% rise in plasma T 3 levels, an increase that was completely abolished when leptin was infused in animals concomitantly treated with rT 3 (Fig. 3A) . On the contrary, and as further illustrated by Fig. 3B , plasma T 4 levels of leptin-infused rats were reduced by 30% compared with those of pair-fed control animals. Such a reduction of plasma T 4 concentrations was only partly normalized by rT 3 administration.
As can be noted in Table 1 , the changes in plasma T 3 and T 4 levels were associated with a trend for plasma TSH levels to be decreased by the intracerebroventricular leptin infusion, although this change did not reach statistical significance. Plasma TSH levels of leptintreated rats receiving rT 3 were similar to those of pair-fed controls.
The expression of UCP1 mRNA in BAT was determined as a marker of sympathetic nervous system activity. As shown in Fig. 4 , central leptin induced an increase in BAT UCP1 mRNA expression, an increase that remained present in the leptin-treated group that received the D2 inhibitor rT 3 (Fig. 4) .
D3 activity, determined in the cortex of the three groups of rats, was found to be unaltered by central leptin infusion, whether in the absence or in the presence of rT 3 infusion (data not shown).
DISCUSSION
We have previously demonstrated that, when leptin was infused for 6 days into the cerebral ventricles of normal (euthyroid) rats, there was no leptin leakage in the periphery and thus no increase in plasma leptin levels, indicating that the effects produced by this hormone, among which is a sustained decrease in food intake, were centrally elicited (9) . By comparing leptininfused rats with vehicle-infused ad libitum-fed controls, and with vehicle-infused animals given the same amount of food as that consumed by the leptin-treated group (i.e., pair-fed controls to mimic leptin-induced hypophagia), we also demonstrated that central leptin administration prevented the decrease in muscle UCP3 expression observed in response to pair feeding (8, 9) . This central leptin effect was, at least partly, mediated by thyroid hormones, as it was not observed in hypothyroid animals (8) . Additionally, in normal animals submitted to food restriction, the well documented decreases in hepatic D1 activity and in plasma T 3 levels did not occur when the animals were administered leptin intracerebroventricularly (1, 8, 24) . This indicated the existence of a stimulatory influence of leptin on hepatic deiodination of T 4 to T 3 and on plasma T 3 levels in euthyroid animals.
D2, a selenoprotein present in the brain, pituitary, and BAT (19) , is the other activating enzyme known to catalyze the 5Ј deiodination of T 4 to the metabolically Values are means Ϯ SE; n ϭ 5-7 animals per group. D1, type I deiodinase; T4, thyroxine. Leptin was infused icv at a dose of 10 g/day. The vehicle used was isotonic saline. Reverse triiodothyronine (rT3) was infused to inhibit the activity of type II deiodinase (D2; 25 nmol ⅐ rat Ϫ1 ⅐ day Ϫ1 ). Vehicle-infused controls were fed the amount of food consumed by leptin-treated rats (pair fed). Intergroup differences, not significant. Mean D1 activity of euthyroid rats was 39.23 Ϯ 5.83 pmol ⅐ min Ϫ1 ⅐ mg
Ϫ1
. Fig. 1 . Schematic representation of the pathways targeted by the experimental design. Rats were made hypothyroid by treatment with propylthiouracil (PTU), which was also used to inhibit hepatic deiodinase type I (D1) activity. As supplement, animals were given 0.6 nmol ⅐ 100 g body wt Ϫ1 ⅐ day Ϫ1 thyroxine (T4) and infused icv for 6 days with vehicle (isotonic saline) or with leptin (10 g/day) in the presence and in the absence of reverse triiodothyronine (rT3) infusion (25 nmol ⅐ rat Ϫ1 ⅐ day
) to inhibit deiodinase type II (D2) activity. Leptin was infused icv into the animals to test its effect on D2 activity and on plasma T3 levels. A potential effect of leptin occurring via an activation of the sympathetic nervous system (Sy) was assessed by measuring the expression of brown adipose tissue (BAT) uncoupling protein-1 (UCP1) mRNA. Vehicle-infused controls were fed the amount of food consumed by leptin-treated rats. CNS, central nervous system. active product T 3 . The study of a potential effect of central leptin administration on D2 activity in euthyroid animals is difficult, because this enzyme is powerfully inhibited by T 4 (40) . However, in view of the postulated key role of D2 in the regulation of tissue-specific thyroid hormone-dependent processes, [e.g., the pituitary feedback mechanism, brain developmental processes, BAT thermogenesis, (3, 7, 22) ], it was of interest to determine whether, in addition to its stimulatory effect on D1, leptin would also affect D2 activity. The hypothesis that leptin might stimulate D2 activity would be in keeping with the observations that central leptin administration promotes an increased sympathetic nervous system activity (12, 23, 35) and that D2 activity, at the level of BAT in particular, was shown to be stimulated by the sympathetic nervous system (4, 38), whereas such is not known to be the case for hepatic D1 activity (19) .
To test the hypothesis that central leptin administration regulates D2 activity, we used an in vivo approach in which D1 activity was strongly inhibited by the use of PTU, which also made the rats hypothyroid. However, to provide substrate for D2 activity, hypothy- ) to inhibit D2 activity. All animals were treated with PTU (0.025% in their drinking water) and supplemented with a low T4 substitution rate (0.6 nmol ⅐ 100 g body wt Ϫ1 ⅐ day
). Vehicleinfused controls were fed the amount of food consumed by leptintreated rats. PF, pair feeding. Values are means Ϯ SE of 5-7 animals per group. *P Յ 0.05 vs. pair fed;
‡ P Յ 0.05 vs. leptin. Fig. 3 . Plasma T3 (A) and T4 levels (B) in rats infused icv for 6 days with vehicle (isotonic saline, Controls) or with leptin (10 g/day) in the presence and absence of rT3 infusion (25 nmol ⅐ rat Ϫ1 ⅐ day Ϫ1 ) to inhibit D2 activity. All animals were treated with PTU (0.025% in their drinking water) and supplemented with a low T4 substitution rate (0.6 nmol ⅐ 100 g body wt Ϫ1 ⅐ day
). Vehicle-infused controls were fed the amount of food consumed by leptin-treated rats. In euthyroid rats, mean plasma levels of T4 were 81.5 Ϯ 8.3 pmol/ml, those of T3 being 1.95 Ϯ 0.15 pmol/ml. Values are means Ϯ SE of 5-7 animals per group. *P Յ 0.05 vs. pair fed; ‡ P Յ 0.05 vs. leptin. Values are means Ϯ SE; n ϭ 5-7 animals per group. Leptin was infused icv at a dose of 10 g/day. The vehicle used was isotonic saline. rT3 was infused to inhibit the activity of D2 (25 nmol ⅐ rat Ϫ1 ⅐ day
). Vehicle-infused controls were fed the amount of food consumed by leptin-treated rats (pair-fed). * P Յ 0.05 vs. pair fed; † P Յ 0.05 vs. leptin.
roid rats were supplemented with T 4 , at a low substitution rate, to avoid inhibition of D2 by T 4 .
We observed that, compared with control rats that were given the same amount of food as that consumed by the leptin-treated animals (pair-fed controls), central leptin administration promoted increases in D2 expression and activity in BAT but not in the brain or in the pituitary. Concomitantly, and compared with those of pair-fed controls, plasma T 3 levels of leptininfused rats were higher, whereas their plasma T 4 concentrations were lower. Such changes in thyroid hormone levels could be the consequence of the stimulatory effect of leptin on BAT D2, in keeping with the reported observation that BAT D2 is not only a local but also a systemic source of T 3 (39) . Indeed, we observed that, when leptin stimulation of BAT D2 activity was prevented by rT 3 , the leptin-induced increase in plasma T 3 and the decrease in plasma T 4 concentrations failed to occur (Fig. 3) . Note that, as rT 3 is a known potent inhibitor of D2 activity at a posttranscriptional level (18), it was not surprising to observe that rT 3 was without effect on D2 mRNA expression in BAT, which was elevated in response to leptin both in the absence and in the presence of rT 3 (Fig. 2 ).
An additional explanation for the increased T 3 plasma levels in the leptin-infused group can be that leptin not only increases T 3 production but could decrease its degradation as well through an effect on D3 activity. Indeed, this enzyme is known to be of importance in the clearance of T 3 , and its activity has been reported to be modulated by the nutritional state (19, 21) . However, we observed that leptin was without any effect on D3 activity in the cerebral cortex. Finally, it is unlikely that the increase in plasma T 3 levels observed in leptin-infused rats could be due to some residual hepatic D1 activity, because under our experimental conditions hepatic D1 activity was inhibited by ϳ90% in the presence of PTU with 0.6 nmol ⅐ 100 g body wt Ϫ1 ⅐ day Ϫ1 T 4 substitution. Plasma TSH levels exhibited a trend toward a decrease in response to intracerebroventricular leptin, although this did not reach statistical significance. This is in contrast to other studies reporting that intracerebroventricular leptin exerts a stimulatory effect on TSH secretion (24, 36) . One major difference between these studies and the present one is the timing of leptin infusion. Here, we observe long-term effects of leptin, and it cannot be ruled out that a potential rise in plasma TSH levels could have been masked by the increased plasma T 3 concentrations observed in response to central leptin administration. In addition, the moderate hypothyroid state of our rats may have affected the TSH response to leptin, since it has been reported that the stimulatory effect of intracerebroventricular leptin is not present in hypothyroid conditions (36) . Yet, in our earlier studies in euthyroid rats, no increase in serum TSH was observed under central leptin infusion (8) .
With regard to the mechanism(s) by which central leptin administration could bring about an increase in BAT D2 activity, an involvement of the sympathetic nervous system might be postulated for the reasons mentioned earlier. This is in keeping with the observation made in the present study that central leptin administration stimulates the expression of UCP1 in BAT of T 4 -substituted hypothyroid rats, as it does in euthyroid animals (6, 9) . Furthermore, such an increase in BAT UCP1 mRNA expression was still observed in leptin-infused rats, in which D2 was inhibited by rT 3 , suggesting that, under our experimental conditions, the increased mRNA expression of UCP1 was not due to local T 3 production (2, 10, 29, 31) but to direct adrenergic stimulation (5, 11, 20, 28, 30) .
The present data, together with those of our previous study (8) , allow us to propose that central leptin could influence the thyroid axis with the following potential series of events. It would enhance the activity of BAT D2 via a likely activation of the sympathetic nervous system, resulting in significant increases in plasma T 3 levels. Such an increase in plasma T 3 concentrations would favor the activity of hepatic D1, given the high sensitivity of this enzyme to T 3 (19) . Leptin action could therefore bear on D2 activity in BAT first and subsequently on D1 activity in the liver, ultimately contributing to increased plasma T 3 levels. Because in the present study PTU was used to block hepatic D1 activity, leaving D2 as the main site for peripheral T 3 production, the relative influence of these two enzymes under physiological conditions cannot be established.
In summary, our data show that central leptin administration brings about a stimulation of BAT D2 activity in T 4 -substituted hypothyroid rats, thus providing yet another aspect of the well substantiated stimulatory effect of leptin on the hypothalamo-pituitary-thyroid axis (13, 15, 24, 26, 36) . Fig. 4 . Expression of UCP1 mRNA in BAT of rats infused icv for 6 days with vehicle (isotonic saline, Controls) or with leptin (10 g/day) in the presence and absence of rT3 infusion (25 nmol ⅐ rat Ϫ1 ⅐ day Ϫ1 ) to inhibit D2 activity. All animals were treated with PTU (0.025% in their drinking water) and supplemented with a low T4 substitution rate (0.6 nmol ⅐ 100 g body wt Ϫ1 ⅐ day
). Vehicle-infused controls were fed the amount of food consumed by leptin-treated rats. Values are means Ϯ SE of 5-7 animals per group. *P Յ 0.05 vs. pair fed.
